Abstract Library

#2924 Everolimus in Patients with Advanced Neuroendocrine Neoplasia: A Real-World Study and Analysis of Long Responders

Introduction: Everolimus is a valid therapeutic option for neuroendocrine tumors (NETs); however, data regarding the long responsders in a real-world setting, outside regulatory trials, are scanty.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rinzivillo M

Authors: Rinzivillo M, De Felice I, Magi L, Prosperi D, Iannicelli E,

Keywords: everolimus, neuroendocrine neoplasia, progressive disease, target therapy,

#2819 Occurrence of Pancreatic Exocrine Insufficiency in Patients with Advanced Neuroendocrine Tumours Treated with Somatostatin Analogue

Introduction: Neuroendocrine neoplasia (NENs) are heterogeneous tumours caracterized by a relatively indolent rate of growth. Usually, in G1 and G2 GEP-NENs, first-line therapy is SSAs, considering their efficacy, good safety profile, and antiproliferative effects. SSA treatment inhibits the production and excretion of pancreatic enzymes and PEI is known to be an adverse effect of SSA treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rinzivillo M

Authors: De Felice I, Rinzivillo M, Pratesi M, Magi L, Annibale B,

Keywords: Pancreatic Exocrine Insufficiency,

#2065 Sunitinib in Patients with Pre-Treated Pancreatic Neuroendocrine Tumors: A Real-World Study

Introduction: Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Rinzivillo M

Authors: Rinzivillo M, Gritti S, Pusceddu S, Spallanzani A, Ibrahim T,

Keywords: Sunitinib, neuroendocrine tumors, pancreas, progressive disease, target therapy,

#2057 Morphological Factors Related to Nodal Metastases in Neuroendocrine Neoplasms of the Appendix. A Multicenter Retrospective Study

Introduction: Appendiceal NETs are usually diagnosed accidentally after appendectomy; the indications for right hemicolectomy are currently based on several parameters (tumor size, grading, Ki-67, localization, mesoappendiceal invasion, lympho-vascular infiltration). Available guidelines are based on scarce evidence inferred by small, retrospective, single institution studies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Brighi N

Authors: Brighi N, Rossi G, Grillo F, Pusceddu S, Rinzivillo M,

Keywords: neuroendocrine neoplasm, appendix, predictive factors, lymph node, surgery, nodal metastases,

#1822 Heterogeneity of Type 1 Gastric Neuroendocrine Neoplasms

Introduction: Type 1 gastric Neuroendocrine Neoplasms (gNENs) are defined when atrophic body gastritis is associated. They are mostly multiple, small, with a low grade histology with low metastatic risk. Data on factors associated with malignant tumor behavior in these patients are scarce.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Rinzivillo M

Authors: Rinzivillo M, Panzuto F, Campana D, Massironi S, Faggiano A,

Keywords: Gastric NEN, Grading ,